Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Xiao Huang; Hai Lin; Feng Huang; Yuning Xie; Ka Hong Wong; Xiaoyu Chen; Dongyue Wu; Aiping Lu; Zhijun Yang

doi:10.1177/1559325819887048

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Xiao Huang, Hai Lin, Feng Huang, Yuning Xie, Ka Hong Wong, Xiaoyu Chen, Dongyue Wu, Aiping Lu^*, Zhijun Yang^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

20 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.

Original language	English
Pages (from-to)	1-14
Number of pages	14
Journal	Dose-Response
Volume	17
Issue number	4
DOIs	https://doi.org/10.1177/1559325819887048
Publication status	Published - 1 Oct 2019

User-Defined Keywords

acute myeloid leukemia
cancer therapy
nanomedicines
nanoparticles

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1559325819887048

Cite this

@article{f78cd52758be4120be7a9b100687c42a,

title = "Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia",

abstract = "Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.",

keywords = "acute myeloid leukemia, cancer therapy, nanomedicines, nanoparticles",

author = "Xiao Huang and Hai Lin and Feng Huang and Yuning Xie and Wong, {Ka Hong} and Xiaoyu Chen and Dongyue Wu and Aiping Lu and Zhijun Yang",

note = "Funding Information: This study is supported by grants from Hong Kong Baptist University Special Development Fund (SDF18-0319-P03). ",

year = "2019",

month = oct,

day = "1",

doi = "10.1177/1559325819887048",

language = "English",

volume = "17",

pages = "1--14",

journal = "Dose-Response",

issn = "1559-3258",

publisher = "International Dose-Response Society",

number = "4",

}

TY - JOUR

T1 - Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

AU - Huang, Xiao

AU - Lin, Hai

AU - Huang, Feng

AU - Xie, Yuning

AU - Wong, Ka Hong

AU - Chen, Xiaoyu

AU - Wu, Dongyue

AU - Lu, Aiping

AU - Yang, Zhijun

N1 - Funding Information: This study is supported by grants from Hong Kong Baptist University Special Development Fund (SDF18-0319-P03).

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.

AB - Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.

KW - acute myeloid leukemia

KW - cancer therapy

KW - nanomedicines

KW - nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85076625603&partnerID=8YFLogxK

U2 - 10.1177/1559325819887048

DO - 10.1177/1559325819887048

M3 - Review article

AN - SCOPUS:85076625603

SN - 1559-3258

VL - 17

SP - 1

EP - 14

JO - Dose-Response

JF - Dose-Response

IS - 4

ER -

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Abstract

User-Defined Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this